Integration of data from multiple sources for simultaneous modelling analysis: experience from nevirapine population pharmacokinetics.
暂无分享,去创建一个
J. Nachega | M. Karlsson | P. Denti | K. Barnes | A. Huitema | J. van der Walt | K. Cohen | T. Kredo | E. Svensson
[1] Jing Yuan,et al. Integration of absorption, distribution, metabolism, and elimination genotyping data into a population pharmacokinetic analysis of nevirapine , 2011, Pharmacogenetics and genomics.
[2] G. Maartens,et al. Interaction between Artemether-Lumefantrine and Nevirapine-Based Antiretroviral Therapy in HIV-1-Infected Patients , 2011, Antimicrobial Agents and Chemotherapy.
[3] M. Youle,et al. Integration of population pharmacokinetics and pharmacogenetics: an aid to optimal nevirapine dose selection in HIV-infected individuals , 2011, The Journal of antimicrobial chemotherapy.
[4] Andrew C. Hooker,et al. Prediction-Corrected Visual Predictive Checks for Diagnosing Nonlinear Mixed-Effects Models , 2011, The AAPS Journal.
[5] T. Snyman,et al. Presence of the CYP2B6 516G> T polymorphism, increased plasma Efavirenz concentrations and early neuropsychiatric side effects in South African HIV-infected patients , 2010, AIDS research and therapy.
[6] C. Verstuyft,et al. Population Pharmacokinetic-Pharmacogenetic Study of Nevirapine in HIV-Infected Cambodian Patients , 2010, Antimicrobial Agents and Chemotherapy.
[7] G. Maartens,et al. Lack of association between stavudine exposure and lipoatrophy, dysglycaemia, hyperlactataemia and hypertriglyceridaemia: a prospective cross sectional study , 2010, AIDS research and therapy.
[8] A. Efron,et al. Randomized controlled trial of trained patient-nominated treatment supporters providing partial directly observed antiretroviral therapy , 2010, AIDS.
[9] N. Ford,et al. Seven-year experience of a primary care antiretroviral treatment programme in Khayelitsha, South Africa , 2010, AIDS.
[10] R. Riley,et al. Meta-analysis of individual participant data: rationale, conduct, and reporting , 2010, BMJ : British Medical Journal.
[11] S. Khoo,et al. Intracellular accumulation of efavirenz and nevirapine is independent of P-glycoprotein activity in cultured CD4 T cells and primary human lymphocytes. , 2009, The Journal of antimicrobial chemotherapy.
[12] P. Perre,et al. Influence of darunavir coadministration on nevirapine pharmacokinetics in HIV‐infected patients: a population approach , 2009, HIV medicine.
[13] S. Richardson,et al. Bayesian graphical models for regression on multiple data sets with different variables , 2008, Biostatistics.
[14] B. Clotet,et al. Once- or twice-daily dosing of nevirapine in HIV-infected adults: a population pharmacokinetics approach. , 2008, The Journal of antimicrobial chemotherapy.
[15] G. Maartens,et al. Outcomes of nevirapine- and efavirenz-based antiretroviral therapy when coadministered with rifampicin-based antitubercular therapy. , 2008, JAMA.
[16] G. Maartens,et al. Effect of rifampicin-based antitubercular therapy and the cytochrome P450 2B6 516G>T polymorphism on efavirenz concentrations in adults in South Africa , 2008, Antiviral therapy.
[17] T. Harrer,et al. Impact of CYP2B6 983T>C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patients. , 2008, The Journal of antimicrobial chemotherapy.
[18] N. Holford,et al. Mechanism-based concepts of size and maturity in pharmacokinetics. , 2008, Annual review of pharmacology and toxicology.
[19] G. Maartens,et al. Effect of rifampicin-based antitubercular therapy on nevirapine plasma concentrations in South African adults with HIV-associated tuberculosis. , 2007, The Journal of antimicrobial chemotherapy.
[20] S. Spector,et al. CYP2B6 genetic variants are associated with nevirapine pharmacokinetics and clinical response in HIV-1-infected children , 2007, AIDS.
[21] Mats O. Karlsson,et al. Implementation of a transit compartment model for describing drug absorption in pharmacokinetic studies , 2007, Journal of Pharmacokinetics and Pharmacodynamics.
[22] R. Chaisson,et al. Hepatotoxicity in an African antiretroviral therapy cohort: the effect of tuberculosis and hepatitis B , 2007, AIDS.
[23] Leon Aarons,et al. Propagation of Population PK and PD Information Using a Bayesian Approach: Dealing with Non-Exchangeability , 2006, Journal of Pharmacokinetics and Pharmacodynamics.
[24] Leon Aarons,et al. Propagation of Population Pharmacokinetic Information Using a Bayesian Approach: Comparison with Meta-Analysis , 2005, Journal of Pharmacokinetics and Pharmacodynamics.
[25] S. Khoo,et al. Intracellular and plasma pharmacokinetics of nevirapine in human immunodeficiency virus‐infected individuals , 2005, Clinical pharmacology and therapeutics.
[26] F. van Leth,et al. Nevirapine and Efavirenz Pharmacokinetics and Covariate Analysis in the 2Nn Study , 2005, Antiviral therapy.
[27] Amalio Telenti,et al. Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients , 2005, Pharmacogenetics and genomics.
[28] E. Niclas Jonsson,et al. Perl-speaks-NONMEM (PsN) - a Perl module for NONMEM related programming , 2004, Comput. Methods Programs Biomed..
[29] B. Gazzard,et al. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study , 2004, The Lancet.
[30] H. Coovadia,et al. MDR1 and CYP3A4 polymorphisms among African, Indian, and white populations in KwaZulu‐Natal, South Africa , 2003, Clinical pharmacology and therapeutics.
[31] F. Aweeka,et al. An LC-MS-MS method for the determination of nevirapine, a non-nucleoside reverse transcriptase inhibitor, in human plasma. , 2003, Journal of pharmaceutical and biomedical analysis.
[32] Paul S Price,et al. Modeling Interindividual Variation in Physiological Factors Used in PBPK Models of Humans , 2003, Critical reviews in toxicology.
[33] Mats O. Karlsson,et al. Use of Prior Information to Stabilize a Population Data Analysis , 2002, Journal of Pharmacokinetics and Pharmacodynamics.
[34] J. Beijnen,et al. Population pharmacokinetics of nevirapine in an unselected cohort of HIV-1-infected individuals. , 2002, British journal of clinical pharmacology.
[35] Michael D. Johnson,et al. Rifampin is a selective, pleiotropic inducer of drug metabolism genes in human hepatocytes: studies with cDNA and oligonucleotide expression arrays. , 2001, The Journal of pharmacology and experimental therapeutics.
[36] P. Reiss,et al. The steady-state pharmacokinetics of nevirapine during once daily and twice daily dosing in HIV-1-infected individuals , 2000, AIDS.
[37] T. Macgregor,et al. Pharmacokinetics of nevirapine and lamivudine in patients with HIV-1 infection , 2000, AAPS PharmSci.
[38] J Wakefield,et al. The Combination of Population Pharmacokinetic Studies , 2000, Biometrics.
[39] J. Boissel,et al. Inter-study variability in population pharmacokinetic meta-analysis: when and how to estimate it? , 2000, Journal of pharmaceutical sciences.
[40] R H Levy,et al. Characterization of the in vitro biotransformation of the HIV-1 reverse transcriptase inhibitor nevirapine by human hepatic cytochromes P-450. , 1999, Drug metabolism and disposition: the biological fate of chemicals.
[41] T. Macgregor,et al. Single dose pharmacokinetics and bioavailability of nevirapine in healthy volunteers , 1999, Biopharmaceutics & drug disposition.
[42] T. Macgregor,et al. Disposition and biotransformation of the antiretroviral drug nevirapine in humans. , 1999, Drug metabolism and disposition: the biological fate of chemicals.
[43] H K Kroemer,et al. The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. , 1999, The Journal of clinical investigation.
[44] R. Murphy,et al. Antiviral effect and pharmacokinetic interaction between nevirapine and indinavir in persons infected with human immunodeficiency virus type 1. , 1999, The Journal of infectious diseases.
[45] Lewis B. Sheiner,et al. Population Pharmacokinetics of Nevirapine, Zidovudine, and Didanosine in Human Immunodeficiency Virus-Infected Patients , 1999, Antimicrobial Agents and Chemotherapy.
[46] J. Beijnen,et al. Rapid determination of nevirapine in human plasma by ion-pair reversed-phase high-performance liquid chromatography with ultraviolet detection. , 1998, Journal of chromatography. B, Biomedical sciences and applications.
[47] J. Corbeil,et al. Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy , 1994, Journal of virology.
[48] Jos H. Beijnen,et al. Piraña and PCluster: A modeling environment and cluster infrastructure for NONMEM , 2011, Comput. Methods Programs Biomed..
[49] Ss Beal,et al. NONMEM User’s Guides. (1989–2009) , 2009 .
[50] K. Cohen,et al. Population pharmacokinetics of nevirapine in combination with rifampicin-based short course chemotherapy in HIV- and tuberculosis-infected South African patients , 2008, European Journal of Clinical Pharmacology.
[51] E N Jonsson,et al. Xpose--an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. , 1999, Computer methods and programs in biomedicine.